Estrella Immunopharma
ESLA
11 hedge funds and large institutions have $341K invested in Estrella Immunopharma in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
47% more capital invested
Capital invested by funds: $232K → $341K (+$109K)
10% more funds holding
Funds holding: 10 → 11 (+1)
0.26% more ownership
Funds ownership: 0.55% → 0.81% (+0.26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$59.1K |
| 2 |
State Street
Boston,
Massachusetts
|
+$22.5K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$17K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$10.7K |
| 5 |
BlackRock
New York
|
+$156 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$16.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.96K |
| 3 |
JP Morgan Chase
New York
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $106K | +$17K | +16,862 | +22% |
|
|
2
UBS Group
Zurich,
Switzerland
| $78.2K | +$59.1K | +58,644 | +899% |
|
|
ASM
3
ATW SPAC Management
New York
| $48K | – | – | – |
|
|
4
BlackRock
New York
| $30.1K | +$156 | +155 | +0.6% |
|
|
5
State Street
Boston,
Massachusetts
| $25.3K | +$22.5K | +22,352 | New |
|
6
Vanguard Group
Malvern,
Pennsylvania
| $24.5K | – | – | – |
|
|
TSS
7
Two Sigma Securities
New York
| $12.8K | +$10.7K | +10,640 | New |
|
|
MCP
8
Maso Capital Partners
Hong Kong
| $12K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $4.55K | -$1.96K | -1,940 | -34% |
|
10
Bank of America
Charlotte,
North Carolina
| $100 | – | – | – |
|
|
11
JP Morgan Chase
New York
| $29 | -$1 | -1 | -4% |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$16.9K | -14,531 | Closed |
|
ESLA Hedge Fund Activity: Q4 2024 in Review
11 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q4 2024, worth a combined $341K — up 47% from $232K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ESLA positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, adding an estimated $59.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $16.9K sold.
- 11 institutional investors held Estrella Immunopharma (ESLA) as of Q4 2024, up from 10 in Q3 2024.
- Funds reported $341K of Estrella Immunopharma stock for Q4 2024, up 47% quarter-over-quarter.
- 2 funds opened new Estrella Immunopharma positions in Q4 2024 and 1 closed out, a net change of +1 holder.
- The largest Estrella Immunopharma buyer in Q4 2024 was UBS Group, an estimated $59.1K added.
- The largest Estrella Immunopharma seller in Q4 2024 was Citadel Advisors, an estimated $16.9K sold.
Based on aggregated 13F filings for Q4 2024.